April 2021

21 Apr Kromatid Receives $2M Investment From BroadOak Capital Partners

Posted at 00:00h in Investment News, News by BroadOak 0 Comments

BroadOak Capital Partners invested growth capital in KromaTiD. KromaTiD sells structural genomic products and tech-enabled services to optimize gene editing for research and clinical purposes. The funding will help accelerate the commercialization of its recently launched direction genomic hybridization In-Site and SCREEN products for gene...

21 Apr KCAS Sells To Vitruvian

Posted at 00:00h in Advisory News, News by BroadOak 0 Comments

BroadOak Capital Partners advised KCAS Bioanalytical and Biomarker Services (“KCAS”) on the sale of the company to Vitruvian. KCAS is a leading contract research organization providing comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and animal health industries. The full press release...